NeoPhore Raises £9.6 Million for Cancer Immunotherapy
NeoPhore, a pioneering small molecule neoantigen immuno-oncology company based in London, UK, has successfully completed an additional funding round, raising an impressive £9.6 million in Series B financing. This latest investment round has significantly bolstered the company’s financial standing, bringing the total funding raised to £31.1 million. The Series B round saw strong participation from NeoPhore’s existing syndicate including CPF managed by Sixth Element Capital, Claris Ventures, and Astellas Venture Management among others. Additionally, the company welcomed three new investors: NEVA SGR, which is the venture capital arm of the Intesa Sanpaolo banking group, LIFTT, a deep-tech focused venture capital firm chaired by Stefano Buono, and Simon Fiduciaria, further expanding its investment base and enhancing future growth opportunities.
Under the strategic leadership of CEO Dr.
Matthew Baker, NeoPhore is dedicated to the discovery and development of innovative small molecule therapies aimed at treating various types of cancer by harnessing the power of the immune system. The company's core focus revolves around the generation of cancer neoantigens within tumors, a process that can be strategically utilized by the patient's immune system to overcome the inherent defense mechanisms employed by cancer cells. This forward-thinking approach is particularly centered on targeting the DNA mismatch repair (MMR) pathway, a vital process known to facilitate the creation of neoantigens, thereby stimulating a robust immune response against a range of cancers. By leveraging these scientific insights, NeoPhore aims to develop cutting-edge immuno-oncology therapeutics that promise to significantly enhance clinical outcomes for patients grappling with cancer.
NeoPhore originated as a spin-out from the University of Turin and PhoreMost Ltd, funded by the CRT Pioneer Fund, marking a strategic venture into the realm of cancer treatment innovation. Reflecting on the company’s progress, Dr. Matthew Baker expressed optimism, stating, “NeoPhore has made excellent progress throughout 2023. With the support of our committed and new investors, along with our research collaborations with academic institutions that are in place, we remain on track to deliver a candidate drug for our lead PMS2 program by early 2025.” This ambitious timeline underscores the company’s commitment to advancing its drug discovery pipeline and enhancing patient outcomes through targeted immuno-oncology solutions.
They've invested in NeoPhore
Get to know these Biotech investors
| Investors | Investment Focus | Startup Investments | Round Size | Connect |
|---|---|---|---|---|
 CPF managed by Sixth Element Capital( ) London  | ||||
 Claris Ventures( ) Turin, Italy  | ||||
 Astellas Venture Management( ) Astellas Venture Management (AVM) is a wholly-owned venture capital organisation... Brisbane, Australia | ||||
 NEVA SGR( ) Milan, Italy | ||||
 LIFTT( ) LIFTT is a venture capital holding company focused on deep tech with a hands-on,... Torino, Italy | ||||
| All investors | All investor sectors | All funded startups | All funding rounds |
Click here for a full list of 7,589+ startup investors in the UK